Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
From Jan 2022: how each company's value moved, whatever its size.
US$ billions, as reported in each year's annual results.
Revenue of the fiscal year. US dollars at each year's exchange rate.
| Measure | Niki BioSolutions, Inc.✕ NIKI | Cessatech A/S✕ 8GN.F |
|---|---|---|
| Profile | ||
| Country | 🇬🇧 UK | 🇩🇰 Denmark |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Founded | 2010 | — |
| Size | ||
| Net income | ||
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | Niki BioSolutions, Inc. | Cessatech A/S |
|---|---|---|
| 2023 | $0 MSEC | — |
| 2022 | $1 MSEC | — |
| 2021 | $2 MSEC | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| $-1 M |
| — |
| Profitability | ||
|---|---|---|
| Return on equity | -6.2% | — |
| Altman Z-score zone | — | — |
|---|
| Data as of | Market cap Mar 2026; ratios FY2025 | Market cap Jul 2023 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.